CCL2 and cancer: Both CCR2 inhibitors and anti-CCL2 monoclonal antibodies have been used in pre-clinical murine models to disrupt this CCL2/CCR2 interaction, showing efficacy both on their own and in combination with other anti-cancer therapies [133,134].